Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence
loader

Kalytera Therapeutics

TSXV:KALY

Leading the Way in CBD Pharmaceuticals

Featured Articles and Interviews
Press Releases

Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products

Kalytera Therapeutics Announces Filing of Short Form Prospectus

Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

Overview

Kalytera Therapeutics, Inc. (TSXV:KALY, OTCQB:KALTF) is a clinical-stage biotechnology company focused on the development of next generation cannabidiol (CBD) pharmaceutical products. The company is pioneering the use of CBD in the prevention and treatment of Graft versus Host Disease (GvHD), a disorder suffered by as much as 50 percent of bone marrow transplant patients. Clinical trials have shown CBD to be potentially efficacious in suppressing the immune-response of the graft cells while simultaneously improving the patient’s ability to fight off infections, both essential for the prevention and treatment of GvHD.

Company Highlights

  • Phase 2 testing underway for the development of a CBD product for the prevention of GvHD
Get access to more exclusive Biotech Stock profiles here.

Interactive Chart

×